Clinical outcomes after interruption of entecavir therapy in HBeAg‐negative chronic hepatitis B patients with compensated cirrhosis. Issue 10 (18th September 2015)

• Record Type: Journal Article
• Authors: Chen, Y. C.; Peng, C. Y.; Jeng, W. J.; Chien, R. N.; Liaw, Y. F.
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 42:Issue 10(2015)
• Page Start: 1182
• Page End: 1191
• Publication Date: 2015-09-18
• Subjects: Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.13409
• Languages: English
• ISSNs: 0269-2813

Abstract

<abstract abstract-type="main" id="apt13409-abs-0001"> <title>Summary</title> <sec id="apt13409-sec-0001" sec-type="section"> <title>Background</title> <p>Long‐term nucleos(t)ide analogues therapy may reduce hepatocellular carcinoma (HCC) in chronic hepatitis B patients with advanced fibrosis or cirrhosis.</p> </sec> <sec id="apt13409-sec-0002" sec-type="section"> <title>Aim</title> <p>To investigate in a retrospective–prospective study whether this beneficial effect would be reduced in cirrhotic patients who discontinued a successful course of entecavir (ETV) therapy.</p> </sec> <sec id="apt13409-sec-0003" sec-type="section"> <title>Methods</title> <p>The study included 586 hepatitis B e antigen (HBeAg)‐negative patients with compensated cirrhosis, mean age of 53.8 ± 10 years and 81% males, treated with ETV for at least 12 months. After ETV therapy for 46.5 ± 22.9 months, 205 patients who achieved hepatitis B virus (HBV) DNA suppression discontinued therapy. The clinical outcomes were assessed and HCC incidence was compared between propensity score (PS)‐matched patients who continued and patients who discontinued ETV therapy by Asian Pacific Association for the Study of Liver stopping rule.</p> </sec> <sec id="apt13409-sec-0004" sec-type="section"> <title>Results</title> <p>During a mean duration of 59.3 ± 19 months after start of ETV therapy, nine and six HCC developed in an estimated annual incidence of 2.3% and 1.6% in 154 PS‐matched patients who continued and who discontinued ETV therapy, respectively (<italic>P</italic> = 0.587). Multivariate Cox proportional hazards regression analyses showed that age (HR 1.065, <italic>P</italic> < 0.001) and HBV DNA (HR 1.216, <italic>P</italic> = 0.048) were the significant factors for HCC development. The rates of adverse clinical outcomes were comparable.</p> </sec> <sec id="apt13409-sec-0005" sec-type="section"> <title>Conclusions</title> <p>The clinical outcomes, including HCC, after cessation of a successful course of entecavir therapy in patients with compensated cirrhosis were comparable to those who continued therapy. The results suggest that this strategy of finite therapy is safe and a feasible alternative to indefinite therapy, especially in a low resources setting.</p> </sec> </abstract>